• T. Blair

Using Blood Plasma from Recovered COVID-19 Patients is Now an Experimental Treatment Option

Minnesota Gov. Tim Walz reported that the Mayo Clinic will begin using blood plasma from recovered COVID-19 patients as an experimental treatment for new cases of the disease.


St. Paul, MN - During yesterday's State of the State address, Governor Tim Walz reported that the Rochester Mayo Clinic will be collecting blood plasma, from individuals who have recovered from COVID-19, and using it to treat new cases of the disease in a program called the Convalescent Plasma Expanded Access Program. This national program is being supported by the American Red Cross and the FDA has authorized the program to use convalescent plasma for patients infected with SARS-CoV-2, the virus that causes COVID-19.


The Mayo Clinic details on their website, "Convalescent plasma refers to blood plasma collected from people who have recovered from COVID-19. That plasma is then used to treat others with advanced illness. The plasma donor must have recovered from, and tested negative for, COVID-19 and be otherwise healthy. The patient is transfused with the donor's plasma, which contains antibodies that can attack the virus and may help patients recover more rapidly."


"The convalescent plasma program at Mayo Clinic, which is led by researcher Michael Joyner, M.D., grew from a national initiative of physicians and investigators from 40 institutions who self organized to investigate the use of convalescent plasma during the COVID-19 pandemic. These institutions include Mayo Clinic, Johns Hopkins University, Washington University, Einstein Medical Center, Icahn School of Medicine at Mount Sinai, Michigan State University, as well as countless other academic medical centers and government agencies seeking to establish a national convalescent plasma program to modify the course of disease."


Watch Gov. Walz's entire 4/5/20 State of the State address (speech begins at 2 min. 32 sec.)


Learn more about the Mayo Clinic's Convalescent Plasma Expanded Access Program.